Literature DB >> 21477078

Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.

Karine A Cohen-Solal1, Kim T Merrigan, Joseph L-K Chan, James S Goydos, Wenjin Chen, David J Foran, Fang Liu, Ahmed Lasfar, Michael Reiss.   

Abstract

Melanoma cells are resistant to transforming growth factor-β (TGFβ)-induced cell-cycle arrest. In this study, we investigated a mechanism of resistance involving a regulatory domain, called linker region, in Smad2 and Smad3, main downstream effectors of TGFβ. Melanoma cells in culture and tumor samples exhibited constitutive Smad2 and Smad3 linker phosphorylation. Treatment of melanoma cells with the MEK1/2 inhibitor, U0126, or the two pan-CDK and GSK3 inhibitors, Flavopiridol and R547, resulted in decreased linker phosphorylation of Smad2 and Smad3. Overexpression of the linker phosphorylation-resistant Smad3 EPSM mutant in melanoma cells resulted in an increase in expression of p15(INK4B) and p21(WAF1) , as compared with cells transfected with wild-type (WT) Smad3. In addition, the cell numbers of EPSM Smad3-expressing melanoma cells were significantly reduced compared with WT Smad3-expressing cells. These results suggest that the linker phosphorylation of Smad3 contributes to the resistance of melanoma cells to TGFβ-mediated growth inhibition. 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477078      PMCID: PMC3108265          DOI: 10.1111/j.1755-148X.2011.00858.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  55 in total

1.  Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3.

Authors:  Isao Matsuura; Guannan Wang; Dongming He; Fang Liu
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

2.  Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo.

Authors:  Delphine Javelaud; Véronique Delmas; Maria Möller; Peggy Sextius; Jocelyne André; Suzanne Menashi; Lionel Larue; Alain Mauviel
Journal:  Oncogene       Date:  2005-11-17       Impact factor: 9.867

3.  Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling.

Authors:  Katharine H Wrighton; Danielle Willis; Jianyin Long; Fang Liu; Xia Lin; Xin-Hua Feng
Journal:  J Biol Chem       Date:  2006-10-10       Impact factor: 5.157

4.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis.

Authors:  Delphine Javelaud; Khalid S Mohammad; Christopher R McKenna; Pierrick Fournier; Flavie Luciani; Maryla Niewolna; Jocelyne André; Véronique Delmas; Lionel Larue; Theresa A Guise; Alain Mauviel
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

Review 5.  Rb/E2F: a two-edged sword in the melanocytic system.

Authors:  Ruth Halaban
Journal:  Cancer Metastasis Rev       Date:  2005-06       Impact factor: 9.264

6.  Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways.

Authors:  Gopal Sapkota; Marie Knockaert; Claudio Alarcón; Ermelinda Montalvo; Ali H Brivanlou; Joan Massagué
Journal:  J Biol Chem       Date:  2006-11-02       Impact factor: 5.157

7.  Rewired ERK-JNK signaling pathways in melanoma.

Authors:  Pablo Lopez-Bergami; Conway Huang; James S Goydos; Dana Yip; Menashe Bar-Eli; Meenhard Herlyn; Keiran S M Smalley; Alka Mahale; Alexey Eroshkin; Stuart Aaronson; Ze'ev Ronai
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

Review 8.  PAI-1 - a potential therapeutic target in cancer.

Authors:  Peter A Andreasen
Journal:  Curr Drug Targets       Date:  2007-09       Impact factor: 3.465

9.  Reversible Smad-dependent signaling between tumor suppression and oncogenesis.

Authors:  Go Sekimoto; Koichi Matsuzaki; Katsunori Yoshida; Shigeo Mori; Miki Murata; Toshihito Seki; Hirofumi Matsui; Jun-ichi Fujisawa; Kazuichi Okazaki
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  The selectivity of protein kinase inhibitors: a further update.

Authors:  Jenny Bain; Lorna Plater; Matt Elliott; Natalia Shpiro; C James Hastie; Hilary McLauchlan; Iva Klevernic; J Simon C Arthur; Dario R Alessi; Philip Cohen
Journal:  Biochem J       Date:  2007-12-15       Impact factor: 3.857

View more
  12 in total

Review 1.  Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.

Authors:  Yuanjun Guo; Manisha Gupte; Prachi Umbarkar; Anand Prakash Singh; Jennifer Y Sui; Thomas Force; Hind Lal
Journal:  J Mol Cell Cardiol       Date:  2017-07-27       Impact factor: 5.000

2.  TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells.

Authors:  Kenji Yumoto; Penny S Thomas; Jamie Lane; Kouichi Matsuzaki; Maiko Inagaki; Jun Ninomiya-Tsuji; Gregory J Scott; Manas K Ray; Mamoru Ishii; Robert Maxson; Yuji Mishina; Vesa Kaartinen
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

Review 3.  The GSK-3 family as therapeutic target for myocardial diseases.

Authors:  Hind Lal; Firdos Ahmad; James Woodgett; Thomas Force
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

4.  Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.

Authors:  Hind Lal; Firdos Ahmad; Jibin Zhou; Justine E Yu; Ronald J Vagnozzi; Yuanjun Guo; Daohai Yu; Emily J Tsai; James Woodgett; Erhe Gao; Thomas Force
Journal:  Circulation       Date:  2014-06-04       Impact factor: 29.690

5.  Definition of smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells.

Authors:  Eunjin Bae; Misako Sato; Ran-Ju Kim; Mi-Kyung Kwak; Kazuhito Naka; Jungsoo Gim; Mitsutaka Kadota; Binwu Tang; Kathleen C Flanders; Tae-Aug Kim; Sun-Hee Leem; Taesung Park; Fang Liu; Lalage M Wakefield; Seong-Jin Kim; Akira Ooshima
Journal:  Cancer Res       Date:  2014-09-09       Impact factor: 12.701

6.  Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation.

Authors:  Sujin Park; Kyung-Min Yang; Yuna Park; Eunji Hong; Chang Pyo Hong; Jinah Park; Kyoungwha Pang; Jihee Lee; Bora Park; Siyoung Lee; Haein An; Mi-Kyung Kwak; Junil Kim; Jin Muk Kang; Pyunggang Kim; Yang Xiao; Guangjun Nie; Akira Ooshima; Seong-Jin Kim
Journal:  J Cancer Prev       Date:  2018-03-30

7.  Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling.

Authors:  Chris Hough; Maria Radu; Jules J E Doré
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

8.  Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.

Authors:  Carole Yolande Perrot; Delphine Javelaud; Alain Mauviel
Journal:  Ann Dermatol       Date:  2013-05       Impact factor: 1.444

9.  Araf kinase antagonizes Nodal-Smad2 activity in mesendoderm development by directly phosphorylating the Smad2 linker region.

Authors:  Xingfeng Liu; Cong Xiong; Shunji Jia; Yu Zhang; Ye-Guang Chen; Qiang Wang; Anming Meng
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.

Authors:  Walid Abushahba; Oyenike O Olabisi; Byeong-Seon Jeong; Rajeev K Boregowda; Yu Wen; Fang Liu; James S Goydos; Ahmed Lasfar; Karine A Cohen-Solal
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.